Correction to "Primary T-cell-based delivery platform for in vivo synthesis of engineered proteins"

DOI: https://doi.org/10.1002/btm2.10658

2024-03-10

Abstract:[This corrects the article DOI: 10.1002/btm2.10605.].

What problem does this paper attempt to address?

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Correction to: A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications

DOI: https://doi.org/10.1093/abt/tbae021

2024-08-27

Abstract:[This corrects the article DOI: 10.1093/abt/tbae013.].
Erratum: Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity

Frontiers Production Office

DOI: https://doi.org/10.3389/fimmu.2023.1353758

2023-12-15

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1194610.].
Corrections to "An Optimized Safe Process from Bench to Pilot cGMP Production of API Eptifibatide Using a Multigram-Scale Microwave-Assisted Solid-Phase Peptide Synthesizer"

Annunziata D'Ercole,Lorenzo Pacini,Giuseppina Sabatino,Matteo Zini,Lorenzo Milli,Francesca Nuti,Arianna Ribecai,Alfredo Paio,Paolo Rovero,Anna Maria Papini

DOI: https://doi.org/10.1021/acs.oprd.2c00224

2022-08-19

Abstract:[This corrects the article DOI: 10.1021/acs.oprd.1c00368.].
Author Correction to ‘bioengineered Mir-124-3p Prodrug Selectively Alters the Proteome of Human Carcinoma Cells to Control Multiple Cellular Components and Lung Metastasis in Vivo’ [acta Pharmaceutica Sinica B 11 (2021) 3950–3965]

Linglong Deng,Hannah Petrek,Mei-Juan Tu,Neelu Batra,Ai-Xi Yu,Ai-Ming Yu

DOI: https://doi.org/10.1016/j.apsb.2023.07.002

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2021.07.027.].
Corrigendum to “Aptamer-Based Cell-Free Detection System to Detect Target Protein” [synth Syst Biotechnol 6 (3) (2021) 209–215]

Junhong Chen,Xiaoyan Zhuang,Jiyang Zheng,Ruofan Yang,Fei Wu,Aihui Zhang,Baishan Fang

DOI: https://doi.org/10.1016/j.synbio.2023.05.001

IF: 4.692

2023-01-01

Synthetic and Systems Biotechnology

Abstract:[This corrects the article DOI: 10.1016/j.synbio.2021.07.004.].
Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Tingting Jiang,Guan Wang,Yao Liu,Lu Feng,Meng Wang,Jie Liu,Yi Chen,Liang Ouyang

DOI: https://doi.org/10.1016/j.apsb.2022.02.028

IF: 14.903

2022-03-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.05.004.].

pharmacology & pharmacy
Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

Fuqiang Xing,Nana Ai,Shigao Huang,Cheng Jiang,Muhammad Jameel Mughal,Wei Ge,Guanyu Wang,Chu-Xia Deng

DOI: https://doi.org/10.3389/fbioe.2022.1039177

IF: 5.7

2022-09-26

Frontiers in Bioengineering and Biotechnology

Abstract:[This corrects the article DOI: 10.3389/fbioe.2022.839078.].

multidisciplinary sciences
Correction: Preparation of a Novel Injectable in Situ-Gelling Nanoparticle with Applications in Controlled Protein Release and Cancer Cell Entrapment

Min Kyung Khang,Jun Zhou,Yihui Huang,Amirhossein Hakamivala,Shuxin Li,Liping Tang

DOI: https://doi.org/10.1039/c8ra90099j

IF: 4.036

2018-01-01

RSC Advances

Abstract:[This corrects the article DOI: 10.1039/C8RA06589F.].
Erratum: A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents

Wang, Hai,Agarwal, Pranay,Zhao, Shuting,Yu, Jianhua,Lu, Xiongbin,He, Xiaoming

DOI: https://doi.org/10.1038/ncomms10350

IF: 16.6

2016-01-01

Nature Communications

Abstract:Nature Communications 6: Article number: 10081 (2015); Published: 1 December 2015; Updated: 7 January 2016 The original version of this Article contained an error in the spelling of ‘theranostic’ in the title of the paper. This has now been corrected in both the PDF and HTML versions of the Article.
Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Zhilin Li,Hao Cai,Zhiqian Li,Long Ren,Xuelei Ma,Hongyan Zhu,Qiyong Gong,Hu Zhang,Zhongwei Gu,Kui Luo

DOI: https://doi.org/10.1016/j.bioactmat.2022.09.016

IF: 18.9

2023-04-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.08.028.].

engineering, biomedical,materials science, biomaterials
Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment"

Hongye He,Feng Li,Rui Tang,Nianhong Wu,Ying Zhou,Yuting Cao,Can Wang,Li Wan,Yang Zhou,Hua Zhuang,Pan Li

DOI: https://doi.org/10.34133/bmr.0088

2024-10-07

Abstract:[This corrects the article DOI: 10.34133/bmr.0064.].
Correction to "Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes"

DOI: https://doi.org/10.1002/hem3.70023

2024-10-07

HemaSphere

Abstract:[This corrects the article DOI: 10.1002/hem3.149.].
Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Yifeng Xia,Jingnan An,Jiaying Li,Wenxing Gu,Yifan Zhang,Songsong Zhao,Cenzhu Zhao,Yang Xu,Bin Li,Zhiyuan Zhong,Fenghua Meng

DOI: https://doi.org/10.1016/j.bioactmat.2023.08.011

IF: 18.9

2024-01-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.08.032.].
Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

DOI: https://doi.org/10.2147/IJN.S500182

2024-10-14

Abstract:[This corrects the article DOI: 10.2147/IJN.S448556.].
Erratum: Addition and Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"

Kin Man Au,Rod Balhorn,Monique C Balhorn,Steven I Park,Andrew Z Wang

DOI: https://doi.org/10.1021/acscentsci.4c00703

2024-05-08

Abstract:[This corrects the article DOI: 10.1021/acscentsci.8b00746.].
A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics: Erratum

Jin Yan,Fanpu Ji,Siqi Yan,Weiming You,Fang Ma,Fanni Li,Yinong Huang,Wenjia Liu,Wangxiao He

DOI: https://doi.org/10.7150/thno.73289

IF: 11.6

2022-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.47243.].

medicine, research & experimental
Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

DOI: https://doi.org/10.1182/blood-2016-06-725010

IF: 20.3

2016-08-18

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2015-04-639203.].
Correction: Intracellular regulation of zinc by metal–organic framework-mediated genome editing for prostate cancer therapy

Yanan Xue,Honglin Tang,Guangpeng Chen,Yubin Pan,Da Li,Yuan Ping

DOI: https://doi.org/10.1039/d3bm90068a

2024-01-13

Biomaterials Science

Abstract:Correction for 'Intracellular regulation of zinc by metal–organic framework-mediated genome editing for prostate cancer therapy' by Yanan Xue et al. , Biomater. Sci. , 2023, https://doi.org/10.1039/d3bm00002h.

materials science, biomaterials
Erratum to “Responsive Inverse Opal Scaffolds with Biomimetic Enrichment Capability for Cell Culture”

Changmin Shao,Yuxiao Liu,Junjie Chi,Jie Wang,Ze Zhao,Yuanjin Zhao

DOI: https://doi.org/10.34133/2022/9850304

IF: 11

2022-02-04

Research

Abstract:[This corrects the article DOI: 10.34133/2019/9783793.].

multidisciplinary sciences

Correction to "Primary T-cell-based delivery platform for in vivo synthesis of engineered proteins"

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction to: A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications

Erratum: Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity

Corrections to "An Optimized Safe Process from Bench to Pilot cGMP Production of API Eptifibatide Using a Multigram-Scale Microwave-Assisted Solid-Phase Peptide Synthesizer"

Author Correction to ‘bioengineered Mir-124-3p Prodrug Selectively Alters the Proteome of Human Carcinoma Cells to Control Multiple Cellular Components and Lung Metastasis in Vivo’ [acta Pharmaceutica Sinica B 11 (2021) 3950–3965]

Corrigendum to “Aptamer-Based Cell-Free Detection System to Detect Target Protein” [synth Syst Biotechnol 6 (3) (2021) 209–215]

Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

Correction: Preparation of a Novel Injectable in Situ-Gelling Nanoparticle with Applications in Controlled Protein Release and Cancer Cell Entrapment

Erratum: A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment"

Correction to "Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes"

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

Erratum: Addition and Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"

A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics: Erratum

Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

Correction: Intracellular regulation of zinc by metal–organic framework-mediated genome editing for prostate cancer therapy

Erratum to “Responsive Inverse Opal Scaffolds with Biomimetic Enrichment Capability for Cell Culture”